Structural modifications that alter the P-glycoprotein efflux properties of compounds

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 4877-4895

  Hitchcock, Stephen A ^a  

^a Envoy Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DERIVATIVE; AMPA RECEPTOR; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BENZOPHENONE DERIVATIVE; BRADYKININ B1 RECEPTOR AGONIST; CARBOXYLIC ACID DERIVATIVE; CETIRIZINE; DESLORATADINE; FEXOFENADINE; GLYCOPROTEIN P; LORATADINE; NALTREXAMINE DERIVATIVE; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; PHENOL DERIVATIVE; PROLINE DERIVATIVE; PROTEIN INHIBITOR; ROFECOXIB; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SULFONAMIDE; TERFENADINE; UREA;

BINDING AFFINITY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLEARANCE; CRYSTAL STRUCTURE; CYTOPLASM; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG SYNTHESIS; EXON; EXTRACELLULAR SPACE; HUMAN; HYDROGEN BOND; HYPERALGESIA; INTESTINE ABSORPTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PLASMA PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS INCONTINENCE; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; P-GLYCOPROTEIN; PERMEABILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862296187     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201136z     Document Type: Review

References (91)

1. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 2008, 36, 268-275
2. Doan, K. M.; M. Humphreys, J. E.; Webster, L. O.; Wring, S. A.; Shampine, L. J.; Serabjit-Singh, C. J.; Adkison, K. K.; Polli, J. W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J. Pharmacol. Exp. Ther. 2002, 303, 1029-1037
3. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E. C. A.; Kasman, I. N.; LaPerle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab. Dispos. 2005, 33, 165-174
4. Raub, T. J. P-Glycoprotein recognition of substrates and circumvention through rational drug design Mol. Pharmaceutics 2006, 3, 3-25
5. Di, L.; Kerns, E. H.; Bezar, I. F.; Petusky, S. L.; Huang, Y. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB J. Pharm. Sci. 2009, 98, 1980-1991
6. Schinkel, A. H.; Smit, J. J. M.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; van der Valk, M. A.; Robanus-Maandag, E. C; te Riele, H. P. J; Berns, A. J. M.; Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 1994, 77, 491-502
7. Chen, C.; Liu, X.; Smith, B. J. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development Curr. Drug Metab. 2003, 4, 272-291
8. Colabufo, N. A.; Berardi, F.; Cantore, M.; Contino, M; Inglese, C.; Niso, M.; Perrone, R. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials J. Med. Chem. 2010, 53, 1883-1897
9. Sakaeda, T.; Nakamura, T.; Okumura, K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy Curr. Top. Med. Chem. 2004, 4, 1385-1398
10. Saier, M. H., Jr; Yen, M. R.; Noto, K.; Tamang, D. G.; Elkan, C. The Transporter Classification Database: recent advances Nucleic Acids Res. 2009, 37, D274-278
11. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 2001, 11, 1156-1166
12. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 1976, 455, 152-162
13. Bauer, B.; Hartz, A. M. S.; Fricker, G.; Miller, D. S. Modulation of p-glycoprotein transport function at the blood-brain barrier Exp. Biol. Med. 2005, 230, 118-127
14. Ameyaw, M. M.; Regateiro, F.; Li, T.; Liu, X.; Tariq, M.; Mobarek, A.; Thornton, N.; Folayan, G. O.; Githang'a, J.; Indalo, A.; Ofori-Adjei, D.; Price-Evans, D. A.; McLeod, H. L. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity Pharmacogenetics 2001, 11, 217-221
15. Droździk, M.; Białecka, M.; Myśliwiec, K.; Honczarenko, K.; Stankiewicz, J.; Sych, Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease Pharmacogenetics 2003, 13, 259-263
16. Callaghan, R.; Crowley, E.; Potter, S.; Kerr, I. D. P-glycoprotein: So many ways to turn it on J. Clin. Pharmacol. 2008, 48, 365-378
17. Bauer, B.; Hartz, A. M. S.; Fricker, G.; Miller, D. S. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier Mol. Pharmacol. 2004, 66, 413-419
18. Bauer, B.; Yang, X.; Hartz, A. M. S.; Olson, E. R.; Zhao, R.; Kalvass, J. C.; Pollack, G. M.; Miller, D. S. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation Mol. Pharmacol. 2006, 70, 1212-1219
19. Linnet, K.; Ejsing, T. B. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs Eur. Neuropsychopharm. 2008, 18, 157-169
20. Remy, S.; Beck, H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy Brain 2006, 129, 18-35
21. Löscher, W.; Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters Nat. Rev. Neurosci. 2005, 6, 591-602
22. Aquilante, C. L.; Letrent, S. P.; Pollack, G. M.; Brouwer, K. L. R. Increased brain P-glycoprotein in morphine tolerant rats Life Sci. 1999, 66, PL47-PL51
23. Seelbach, M. J.; Brooks, T. A.; Egleton, R. D.; Davis, T. P. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein J. Neurochem. 2007, 102, 1677-1690
24. Cheng, Z.; Zhang, J.; Liu, H.; Li, Y.; Zhao, Y.; Yang, E. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption Drug Metab. Dispos. 2010, 38, 1355-1361
25. Bartels, A. L.; Kortekaas, R.; Bart, J.; Willemsen, A. T. M.; de Klerk, O. L.; de Vries, J. J.; van Oostrom, J. C. H.; Leenders, K. L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration Neurobiol. Aging 2009, 30, 1818-1824
26. Bartels, A. L.; de Klerk, O. L.; Kortekaas, R.; de Vries, J. J.; Leenders, K. L. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease Curr. Top. Med. Chem. 2010, 10, 1775-1784
27. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H. K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans Pharmacogenetics 2002, 12, 535-541
28. Brenn, A.; Grube, M.; Peters, M.; Fischer, A.; Jedlitschky, G.; Kroemer, H. K.; Warzok, R. W.; Vogelgesang, S. Beta-amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice Int. J. Alzheimers. Dis. 2011, 10.4061/2011/690121
29. Lee, C. A.; Cook, J. A.; Reyner, E. L.; Smith, D. A. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states Expert Opin. Drug Metab. Toxicol. 2010, 6, 603-619
30. Shaffer, C. L. Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure-response relationships Annu. Rep. Med. Chem. 2010, 45, 55-70
31. Wong, D. F.; Tauscher, J.; Grunder, G. The role of imaging in proof of concept for CNS drug discovery and development Neuropsychopharmacology 2008, 34, 187-203
32. Katoh, M.; Suzuyama, N.; Takeuchi, T.; Yoshitomi, S.; Asahi, S.; Yokoi, T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport J. Pharm. Sci. 2006, 95, 2673-2683
33. Syvänen, S.; Lindhe, Ö.; Palner, M.; Kornum, B. R.; Rahman, O.; Långström, B.; Knudsen, G. M.; Hammarlund-Udenaes, M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab. Dispos. 2009, 37, 635-643
34. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 2001, 299, 620-628
35. Schwab, D.; Fischer, H.; Tabatabaei, A.; Poli, S.; Huwyler, J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery J. Med. Chem. 2003, 46, 1716-1725
36. Kell, D. B.; Dobson, P. D.; Oliver, S. G. Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only Drug Discovery Today 2011, 16, 704-714
37. Liu, X.; Chen, C. Strategies to optimize brain penetration in drug discovery Curr. Opin. Drug Discovery Dev. 2005, 8, 505-512
38. Mensch, J.; Melis, A.; Mackie, C.; Verreck, G.; Brewster, M. E.; Augustijns, P. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability Eur. J. Pharm. Biopharm. 2010, 74, 495-502
39. Schinkel, A. H.; Mayer, U.; Wagenaar, E.; Mol, C. A. A. M.; van Deemter, L.; Smit, J. J. M.; van der Valk, M. A.; Voordouw, A. C.; Spits, H.; van Tellingen, O.; Zijlmans, J. M.; Fibbe, W. E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4028-4033
40. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res. 1993, 53, 4595-4602
41. Cutler, L.; Howes, C.; Deeks, N. J.; Buck, T. L.; Jeffrey, P. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier J. Pharm. Sci. 2006, 95, 1944-1953
42. Kodaira, H.; Kusuhara, H.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone J. Pharmacol. Exp. Ther. 2010, 333, 788-796
43. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration Drug Metab. Dispos. 2006, 34, 1443-1447
44. Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios Drug Metab. Dispos. 2007, 35, 660-666
45. Jeffrey, P.; Summerfield, S. G. Challenges for blood-brain barrier (BBB) screening Xenobiotica 2007, 37, 1135-1151
46. Watson, J.; Wright, S.; Lucas, A.; Clarke, K. L.; Viggers, J.; Cheetham, S.; Jeffrey, P.; Porter, R.; Read, K. D. Receptor occupancy and brain free fraction Drug Metab. Dispos. 2009, 37, 753-760
47. Dagenais, C.; Avdeef, A.; Tsinman, O.; Dudley, A.; Beliveau, R. P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model Eur. J. Pharm. Sci. 2009, 38, 121-137
48. Wager, T. T.; Villalobos, A.; Verhoest, P. R.; Hou, X.; Shaffer, C. L. Strategies to optimize the brain availability of central nervous system drug candidates Expert Opin. Drug Discovery. 2011, 6, 371-381
49. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
50. Fridén, M.; Winiwarter, S.; Jerndal, G.; Bengtsson, O.; Wan, H.; Bredberg, U.; Hammarlund-Udenaes, M.; Antonsson, M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids J. Med. Chem. 2009, 52, 6233-6243
51. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583
52. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 2010, 1, 435-449
53. Meanwell, N. A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1345-1410
54. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323, 1718-1722
55. Klepsch, F.; Ecker, G. F. Impact of the recent mouse P-glycoprotein structure for structure-based ligand design Mol. Inf. 2010, 29, 276-286
56. Dolghih, E.; Bryant, C.; Renslo, A. R.; Jacobson, M. P. Predicting binding to P-glycoprotein by flexible receptor docking PLoS Comput. Biol. 2011, 7, e1002083
57. Demel, M. A.; Schwaha, R.; Krämer, O.; Ettmayer, P.; Haaksma, E. E.; Ecker, G. F. In silico prediction of substrate properties for ABC-multidrug transporters Expert Opin. Drug Metab. Toxicol. 2008, 4, 1167-1180
58. Huang, H.; Player, M. R. Bradykinin B1 receptor antagonists as potential therapeutic agents for pain J. Med. Chem. 2010, 53, 5383-5399
59. Kuduk, S. D.; Di Marco, C. N.; Chang, R. K.; Wood, M. R.; Schirripa, K. M.; Kim, J. J.; Wai, J. M.; C. DiPardo, R. M.; Murphy, K. L.; Ransom, R. W.; Harrell, C. M.; Reiss, D. R.; Holahan, M. A.; Cook, J.; Hess, J. F.; Sain, N.; Urban, M. O.; Tang, C.; Prueksaritanont, T.; Pettibone, D. J.; Bock, M. G. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists J. Med. Chem. 2007, 50, 272-282
60. Yuan, Y.; Li, G.; He, H.; Stevens, D. L.; Kozak, P.; Scoggins, K. L.; Mitra, P.; Gerk, P. M.; Selley, D. E.; Dewey, W. L.; Zhang, Y. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists ACS Chem. Neurosci. 2011, 2, 346-351
61. Hyafil, F.; Vergely, C.; Du, V. P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative Cancer Res. 1993, 53, 4595-4602
62. Olsen, R. A.; Liu, L.; Ghaderi, N.; Johns, A.; Hatcher, M. E.; Mueller, L. J. The amide rotational barriers in picolinamide and nicotinamide: NMR and ab initio studies J. Am. Chem. Soc. 2003, 125, 10125-10132
63. Hamada, Y.; Kiso, Y. Recent progress in the drug discovery of non-peptidic BACE1 inhibitors Expert Opin. Drug Discovery 2009, 4, 391-416
64. Silvestri, R. Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease Med.Res.Rev. 2009, 29, 295-338
65. Varghese, J., Ed. BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease; John Wiley & Sons: New York, 2010.
66. Varatharajan, L.; Thomas, S. A. The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research Antiviral Res. 2009, 82, A99-A109
67. Xue, Q.; Albrecht, B. K.; Andersen, D. L.; Bartberger, M.; Brown, J.; Brown, R.; Chaffee, S. C.; Cheng, Y.; Croghan, M.; Graceffa, R.; Harried, S.; Hitchcock, S.; Hungate, R.; Judd, T.; Kaller, M.; Kreiman, C.; La, D.; Lopez, P.; Masse, C. E.; Monenschein, H.; Nguyen, T.; Nixey, T.; Patel, V. F.; Pennington, L.; Weiss, M.; Yang, B.; Zhong, W. Preparation of 2-Hydroxy-1,3-diaminoalkanes including Spiro Substituted Chroman Derivatives as β-Secretase Modulators and Their Use for Treatment Alzheimer's Disease and Related Condition. PCT Intl. Appl. WO2007061930.
68. Hitchcock, S.; Orally Active, Brain Penetrant Beta-Secretase (BACE) Inhibitors: Consolidating Property-Based and Structure-Based Drug Design. 3rd International Symposium on Advances in Synthetic and Medicinal Chemistry, Kiev, Ukraine, August 23, 2009.
69. Hennig, L.; Ayala-Leon, K.; Angulo-Cornejo, J.; Richter, R.; Beyer, L. Fluorine hydrogen short contacts and hydrogen bonds in substituted benzamides J. Fluorine Chem. 2009, 130, 453-460
70. Fritz, H.; Winkler, T. Weitreichende kopplung zwischen protonen und fluor in 2-fluorbenzamiden Helv. Chim. Acta 1974, 57, 836-839
71. Ward, S. E.; Harries, M.; Aldegheri, L.; Andreotti, D.; Ballantine, S.; Bax, B. D.; Harris, A. J.; Harker, A. J.; Lund, J.; Melarange, R.; Mingardi, A.; Mookherjee, C.; Mosley, J.; Neve, M.; Oliosi, B.; Profeta, R.; Smith, K. J.; Smith, P. W.; Spada, S.; Thewlis, K. M.; Yusaf, S. P. Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2- propanesulfonamide, a novel clinical AMPA receptor positive modulator J. Med. Chem. 2010, 53, 5801-5812
72. Shi, F.; Shen, J. K.; Chen, D.; Fog, K.; Thirstrup, K.; Hentzer, M.; Karlsson, J.-J.; Menon, V.; Jones, K. A.; Smith, K. E.; Smith, G. Discovery and SAR of a series of agonists at orphan G protein-coupled receptor 139 ACS Med. Chem. Lett. 2011, 2, 303-306
73. Wakenhut, F.; Allan, G. A.; Fish, P. V.; Jonathan Fray, M.; Harrison, A. C.; McCoy, R.; Phillips, S. C.; Stobie, A.; Westbrook, D.; Westbrook, S. L.; Whitlock, G. A. N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: Impact of small structural modifications on P-gp recognition and CNS penetration Bioorg. Med. Chem. Lett. 2009, 19, 5078-5081
74. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18, 4872-4875
75. Bergman, J. M.; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.; Reiss, D. R.; Ransom, R. W.; Meacham Harrell, C.; Pettibone, D. J.; Lemaire, W.; Murphy, K. L.; Li, C.; Prueksaritanont, T.; Winrow, C. J.; Renger, J. J.; Koblan, K. S.; Hartman, G. D.; Coleman, P. J. Proline bis-amides as potent dual orexin receptor antagonists Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430
76. Giblin, G. M. P.; Billinton, A.; Briggs, M.; Brown, A. J.; Chessell, I. P.; Clayton, N. M.; Eatherton, A. J.; Goldsmith, P.; Haslam, C.; Johnson, M. R.; Mitchell, W. L.; Naylor, A.; Perboni, A.; Slingsby, B. P.; Wilson, A. W. Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]- 1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain J. Med. Chem. 2009, 52, 5785-5788
77. Verhoest, P. R.; Sawant Basak, A.; Parikh, V.; Hayward, M.; Kauffman, G. W.; Paradis, V.; McHardy, S. F.; McLean, S.; Grimwood, S.; Schmidt, A. W.; Vanase-Frawley, M.; Freeman, J.; Van Deusen, J.; Cox, L.; Wong, D.; Liras, S. Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl) propan-1-amine, PF-4455242 J. Med. Chem. 2011, 54, 5868-5877
78. Dosaka-Akita, K.; Tortella, F. C.; Holaday, J. W.; Long, J. B. The kappa opioid agonist U-50488H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats J. Pharmacol. Exp. Ther. 1993, 264, 631-637
79. Su, D.-S.; Lim, J. L.; Tinney, E.; Wan, B.-L.; Murphy, K. L.; Reiss, D. R.; Harrell, C. M.; O'Malley, S. S.; Ransom, R. W.; Chang, R. S. L.; Pettibone, D. J.; Yu, J.; Tang, C.; Prueksaritanont, T.; Freidinger, R. M.; Bock, M. G.; Anthony, N. J. J. Med. Chem. 2008, 51, 3946-3952
80. Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Coleman, P. J.; Garbaccio, R. M.; Fraley, M. E.; Zrada, M. M.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Tao, W.; Abrams, M. T.; South, V. J.; Huber, H. E.; Kohl, N. E.; Hartman, G. D. Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein Bioorg. Med. Chem. Lett. 2007, 17, 2697-2702
81. Guo, Q.; Chandrasekhar, J.; Ihle, D.; Wustrow, D. J.; Chenard, B. L.; Krause, J. E.; Hutchison, A.; Alderman, D.; Cheng, C.; Cortright, D.; Broom, D.; Kershaw, M. T.; Simmermacher-Mayer, J.; Peng, Y.; Hodgetts, K. J. 1-Benzylbenzimidazoles: the discovery of a novel series of bradykinin B(1) receptor antagonists Bioorg. Med. Chem. Lett. 2008, 18, 5027-5031
82. Chen, C.; Hanson, E.; Watson, J. W.; Lee, J. S. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists Drug Metab. Dispos. 2003, 31, 312-318
83. Broccatelli, F.; Carosati, E.; Cruciani, G.; Oprea, T. I. Transporter-mediated efflux influences CNS side effects: ABCB1, from antitarget to target Mol. Inf. 2010, 29, 16-26
84. Nagase, T.; Mizutani, T.; Ishikawa, S.; Sekino, E.; Sasaki, T.; Fujimura, T.; Ito, S.; Mitobe, Y.; Miyamoto, Y.; Yoshimoto, R.; Tanaka, T.; Ishihara, A.; Takenaga, N.; Tokita, S.; Fukami, T.; Sato, N. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists J. Med. Chem. 2008, 51, 4780-4789
85. L. Mercer, S.; Coop, A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance Curr. Top. Med. Chem. 2011, 11, 1157-1164
86. Cunningham, C. W.; Mercer, S. L.; Hassan, H. E.; Traynor, J. R.; Eddington, N. D.; Coop, A. Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs J. Med. Chem. 2008, 51, 2316-2320
87. Mahar Doan, K. M.; Wring, S. A.; Shampine, L. J.; Jordan, K. H.; Bishop, J. P.; Kratz, J.; Yang, E.; Serabjit-Singh, C. J.; Adkison, K. K.; Polli, J. W. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding Pharmacology 2004, 72, 92-98
88. Zhao, R.; Kalvass, J. C.; Yanni, S. B.; Bridges, A. S.; Pollack, G. M. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration Drug Metab. Dispos. 2009, 37, 529-535
89. Helal, C. J.; Kang, Z.; Hou, X.; Pandit, J.; Chappie, T. A.; Humphrey, J. M.; Marr, E. S.; Fennell, K. F.; Chenard, L. K.; Fox, C.; Schmidt, C. J.; Williams, R. D.; Chapin, D. S.; Siuciak, J.; Lebel, L.; Menniti, F.; Cianfrogna, J.; Fonseca, K. R.; Nelson, F. R.; O'Connor, R.; Macdougall, M.; McDowell, L.; Liras, S. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A Inhibitor lead series for the treatment of schizophrenia J. Med. Chem. 2011, 54, 4536-4547
90. Swinney, D. C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discovery 2011, 10, 507-519
91. Conn, J. P.; Christopoulos, A.; Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8, 41-54